Table of Contents
- Early Promise, Followed by Disappointments
- A New Breakthrough in High-Risk Patients
- What This Means for the Rest of Us
- References
Omega-3 research has had its share of failures — but a landmark new trial points to something significant. The evidence on fish oil and cardiovascular health has been mixed for years, with major studies producing conflicting results. A new randomised controlled trial now offers fresh insight into how Omega-3 fatty acids may protect against major cardiovascular events, and what the findings mean for dosing decisions.
Early Promise, Followed by Disappointments
Despite the initial promising studies on Omega-3 and heart health, the research journey has been rocky.
A 2006 systematic review found that increased consumption of n-3 fatty acids from fish or fish-oil supplements — but not alpha-linolenic acid — reduced the rates of all-cause mortality, cardiac and sudden death, and possibly stroke [1].
But by 2012, things started to go wrong.
In 2012, the findings were published from a large study of 12,536 patients who had type 2 diabetes or were at elevated risk of it. These patients were also at high risk for cardiovascular events like heart attacks and strokes. One group in the study took a 1 g Omega-3 supplement daily [2].
After a median follow-up of 6.2 years, heart-related deaths in the Omega-3 group were not significantly lower than in the placebo group. The incidence of the primary outcome was:
- 9.1% in the Omega-3 group (574 patients)
- 9.3% in the placebo group (581 patients)
- Hazard ratio: 0.98 (95% CI: 0.87 to 1.10; P=0.72) [2]
There also was not a significant difference in heart attacks and strokes. For major vascular events:
- Omega-3 group: 16.5% (1034 patients)
- Placebo group: 16.3% (1017 patients)
- Hazard ratio: 1.01 (95% CI: 0.93 to 1.10; P=0.81) [2]
And then came the STRENGTH trial, published in 2020. This was a massive study of over 13,000 patients taking statins who were at high risk for heart problems. It spanned 22 countries across North America, Europe, South America, Asia, Australia, New Zealand, and South Africa [3].
The study tested high-dose Omega-3 fatty acids (EPA and DHA) compared with corn oil.
It was actually stopped early, because the data was clear: no significant difference when it came to major cardiovascular events like heart attacks and strokes.
- Hazard ratio: 0.99 (95% CI: not provided in summary) [3]
The only bright spot came from the VITAL trial in 2018. It included 25,871 participants with a follow-up period of 5.3 years. One group took 1 g of Omega-3 daily [4].
That group had a 28% lower risk of heart attack compared to placebo.
- Hazard ratio for total myocardial infarction: 0.72 (95% CI: 0.59 to 0.90) [4]
To make sense of the conflicting data, the Mayo Clinic conducted a large meta-analysis. This included 40 studies and 135,267 participants.
Here is what they found:
-
Heart attack risk dropped by 13%
- Relative risk (RR): 0.87 (95% CI: 0.80 to 0.96)
-
Fatal heart attack risk dropped by 35%
- RR: 0.65 (95% CI: 0.46 to 0.91)
-
Number needed to treat (NNT):
- 272 for heart attacks
- 128 for fatal heart attacks [5]
But there remained a number of important questions — about dosing, the best forms of Omega-3, and the risks of a dangerous heart rhythm problem known as atrial fibrillation. More on that below.
Overall, from the VITAL trial and the Mayo Clinic meta-analysis, the data show some real and important benefits — even though the early hype has cooled a bit.
A New Breakthrough in High-Risk Patients
Given these potential heart health benefits, researchers wanted to test Omega-3 in a group of patients where virtually nothing else had worked.
The results appear to be a game changer — and the implications extend beyond this specific patient group.
The patient group in question is those with kidney failure who are undergoing dialysis. Dialysis is where a machine filters blood because the kidneys can no longer do so.
This is a surprisingly large group — estimated at around 3 million people globally. But dialysis machines do not perform as well as healthy kidneys.
One of the major problems dialysis patients face is a very high mortality rate, especially from heart disease. In fact, around 40–50% of those on dialysis die from heart-related problems [6].
Finding interventions that reduce this number has proven extremely difficult.
Example 1: Statins
These cholesterol-lowering drugs have shown impressive benefits in the general population. For example:
- Statins reduce cardiovascular events by ~25% per 38.6 mg/dL LDL reduction
- Long-term LDL-C reduction (over 40 years) may lower cardiovascular mortality by 50–55%
- The largest absolute benefits occur in high-risk groups [7]
But in dialysis patients, statins have been a disappointment.
A 2015 meta-analysis found no significant impact on all-cause or cardiovascular mortality [8].
Example 2: Spironolactone
This is a medication commonly used for heart failure and hypertension.
In a study of veterans with heart failure and preserved ejection fraction, spironolactone reduced all-cause mortality by 21%.
- Hazard ratio: 0.79 (95% CI: 0.71–0.87; P<0.0001) [9]
But when tested in dialysis patients, it made no difference.
A 2025 systematic review concluded it had little to no effect on cardiovascular mortality in this population [10].
The New Omega-3 Study
Against this backdrop of repeated failures, researchers asked a bold question:
Could a fish oil supplement succeed where powerful heart medications had failed?
The study was large and well-designed:
- Conducted across 26 sites in Canada and Australia
- Included 1,296 adult dialysis patients
-
One group received 4 g/day of Omega-3
- (1.6 g EPA and 0.8 g DHA)
- The other group received a corn oil placebo
- Follow-up period: 3.5 years [11]
The results were startling.
Major Cardiovascular Events
These included heart attacks, strokes, and heart-related deaths.
-
The Omega-3 group had a 43% lower risk
- Hazard ratio: 0.57 (95% CI: 0.47 to 0.70; P<0.001) [11]
Specific Outcomes:
-
Cardiac deaths:
- 45% lower risk
- HR: 0.55 (95% CI: 0.40 to 0.75)
-
Heart attacks (fatal and nonfatal):
- 44% lower risk
- HR: 0.56 (95% CI: 0.40 to 0.80)
-
Peripheral vascular disease leading to amputation:
- 43% lower risk
- HR: 0.57 (95% CI: 0.38 to 0.86)
-
Strokes (fatal and nonfatal):
- 63% lower risk
- HR: 0.37 (95% CI: 0.18 to 0.76) [11]
This level of benefit was completely unexpected — and extremely promising.
What This Means for the Rest of Us
This new study provides compelling data on the potential cardiovascular benefits of Omega-3.
The promise for an extremely high-risk group is substantial.
But most people do not have end-stage kidney disease. So what does this mean for the general population?
The evidence so far has a degree of tension.
On the one hand, impressive early studies and meta-analyses have shown benefits. On the other hand, major disappointments like the STRENGTH trial showed no benefit despite a large sample size and long follow-up.
But this new trial does two things:
1. It provides additional support to the existing evidence that Omega-3 likely has real potential to protect heart health
2. It suggests stronger and more consistent results may be achievable in the general population — if dosing and formulation are right
And dosing, as the evidence makes clear, is complex.
In the Mayo Clinic meta-analysis, the authors stated:
"Supplementation with EPA and DHA is an effective lifestyle strategy for CVD prevention, and the protective effect probably increases with dosage." [5]
But atrial fibrillation (AF) risk also appears to increase with dosage.
A separate meta-analysis found that:
- Marine Omega-3s increased AF risk by 25% overall
-
At >1 g/day:
- 49% increased risk (HR: 1.49; 95% CI: 1.04–2.15)
-
At ≤1 g/day:
- 12% increased risk (HR: 1.12; 95% CI: 1.03–1.22)
- P for interaction <0.001, indicating dose matters [12]
The latest dialysis study used 4 g/day [11]. In patients facing such high mortality risk, a modest increase in atrial fibrillation may represent a reasonable trade-off. For the general population, however, the risk-benefit calculation is different.
The current evidence base suggests that for most adults, 1 g of Omega-3 per day balances cardiovascular benefit against the dose-dependent atrial fibrillation signal — consistent with the VITAL trial's 28% heart attack reduction at this dose [4].
It is worth noting that some prescription-grade, high-purity Omega-3 products — such as icosapent ethyl (Vascepa) — have been studied specifically in very high-risk patients already on statins, and have shown additional cardiovascular benefit. These are pharmaceutical-grade EPA-only formulations at very high doses (4 g/day), distinct from standard over-the-counter fish oil, and are prescribed and monitored by clinicians for specific patient groups. Their results do not automatically translate to general fish-oil supplementation, but they do reinforce that EPA plays a meaningful role in cardiovascular risk reduction when applied in the right context.
As with any supplement, individual risk factors and personal medical circumstances vary. Consulting a healthcare professional is recommended before starting or adjusting Omega-3 supplementation.
References
1. https://pubmed.ncbi.nlm.nih.gov/16825676/
2. https://pubmed.ncbi.nlm.nih.gov/22686415/
3. https://jamanetwork.com/journals/jama/fullarticle/2773120
4. https://www.nejm.org/doi/full/10.1056/NEJMoa1811403
5. https://www.mayoclinicproceedings.org/article/S0025-6196%2820%2930985-X/fulltext
6. https://www.nejm.org/doi/full/10.1056/NEJMe2515057
7. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2773162
8. https://pubmed.ncbi.nlm.nih.gov/26139229/
9. https://www.ahajournals.org/doi/10.1161/JAHA.123.032231
10. https://pubmed.ncbi.nlm.nih.gov/40840478/
